Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 600 in its research report dated August 05, 2022.
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 780 in its research report dated August 04, 2022.
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 610 in its research report dated August 04, 2022.
Total revenue from operations stood at Rs 3,744 crore in the June quarter as against Rs 4,270 crore in the year-ago period, Lupin said in a statement.
"Our numbers are muted in the quarter but we expect a strong bounceback from September quarter," Nilesh Gupta, managing director, Lupin, said.
Net Sales are expected to decrease by 6.2 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs 4,007.1 crore, according to ICICI Direct.
Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.
The US Food and Drug Administration (US FDA) had inspected the facility in March 2022, the company said in a regulatory filing.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ivacaftor tablets, 150 mg strength, Lupin said in a statement.
ICICI Direct recommended hold rating on Lupin with a target price of Rs 610 in its research report dated May 20, 2022.
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 780 in its research report dated May 19, 2022.
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 590 in its research report dated May 19, 2022.
Near-term growth visibility is low due to a lack of major product launches, aggravating pricing erosion and input cost pressure for Lupin
"It paves the way for us to bring quality paediatric formulations to the growing needs of patients in China," Fabrice Egros, president - corporate development and growth markets, Lupin, said.
The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg), Lupin said in a statement.
Net Sales are expected to increase by 6.3 percent Y-o-Y (down 3.3 percent Q-o-Q) to Rs 4,021.7 crore, according to Prabhudas Lilladher.
The acquisition will strengthen the company’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products, the Mumbai-based drug maker said in a statement.
The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL, Lupin said in a statement.
The Mumbai-based drug firm's product is the generic equivalent of Lundbeck Pharmaceuticals' Sabril for Oral Solution.